Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA

Cancer Immunity

Volumn 4, Issue , 2004, Pages

  Liénard, Danielle ^a   Rimoldi, Donata ^b   Marchand, Marie ^c,d   Dietrich, Pierre Yves ^e   Van Baren, Nicolas ^c   Geldhof, Christine ^a   Batard, Pascal ^a   Guillaume, Philippe ^b   Ayyoub, Maha ^a   Pittet, Mikaël J ^a   Zippelius, Alfred ^a   Fleischhauer, Katharina ^f   Lejeune, Ferdy ^a   Cerottini, Jean Charles ^a,b   Romero, Pedro ^a,b   Speiser, Daniel E ^a,g  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^g Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

Clinical trial; Immunological adjuvants; Immunological monitoring; Melan A peptide; Melanoma; Vaccination

Indexed keywords

CD28 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; INFLUENZA VACCINE; INTERLEUKIN 2; MELAN A; MELANOMA VACCINE; PEPTIDE DERIVATIVE; QS 21;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHILIA; EX VIVO STUDY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOFLUORESCENCE TEST; INJECTION SITE REACTION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MELANOMA; MUCUS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; SKIN INFLAMMATION; SKIN METASTASIS; SWEATING; T LYMPHOCYTE; VACCINATION;

EID: 13444249836     PISSN: 14249634     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Jäger D, Jâger E, Knuth A. Vaccination for malignant melanoma: recent developments. Oncology 2001 ; 60: 1-7. (PMID: 11150901)
2. Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 2001; 1: 497-510. (PMID: 11727521)
3. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 2001; 1: 277-90. (PMID: 11727535)
4. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7. (PMID: 10204484)
5. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-52. (PMID: 7516411)
6. Jäger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens. Int J Cancer 1996; 66: 162-9. (PMID: 8603805)
7. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3: 37-44. (PMID: 10537339)
8. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5: 2756-65. (PMID: 10537339)
9. Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher F, Liénard D, Lejeune F, Cerottini JC, Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003; 13: 461-72. (PMID: 15001165)
10. Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003; 9: 1301-12. (PMID: 12684398)
11. Speiser DE, Ohashi PS. Activation of cytotoxic T cells by solid tumours? Cell Mol Life Sci 1998; 54: 263-71. (PMID: 9575338)
12. Overwijk WW, Restifo NP. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol 2001; 22: 5-7. (PMID: 11286676)
13. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6. (PMID: 8810254)
14. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P. Ex vivo analysis of human antigen specific CD8+ T cell responses: quality assessment of fluorescent HLA-A2 multimers and IFN-gamma ELISPOT assays for patient immune monitoring. J Immunother. In press 2004.
15. Merkenschlager M, Beverley PC. Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1 ). Int Immunol 1989; 1: 450-9. (PMID: 2562244)
16. Pittet MJ, Speiser DE, Liénard D, Valmori D, Guillaume P, Dutoit V, Rimoldi D, Lejeune F, Cerottini JC, Romero P. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001; 7: 796s-803s. (PMID: 11300475)
17. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12. (PMID: 10537110)
18. Azuma M, Phillips JH, Lanier LL. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150: 1147-59. (PMID: 8381831)
19. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190: 705-15. (PMID: 10477554)
20. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996; 93: 7855-60. (PMID: 8755566)
21. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-83. (PMID: 8653680)
22. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18: 267-8. (PMID: 9190110)
23. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7. (PMID: 9500606)
24. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22: 431-40. (PMID: 10546159)
25. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998; 4: 316-23. (PMID: 9815296)
26. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78. (PMID: 10587357)
27. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-8. (PMID: 11522640)
28. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 2002; 8: 967-72. (PMID: 12006508)
29. Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, Rubio-Godoy V, Walker PR, Rimoldi D, Liénard D, Cerottini JC, Romero P, Dietrich PY. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002; 168: 4231-40. (PMID: 11937585)
30. Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Liénard D, Speiser DE. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003; 9: 669-77. (PMID: 12576434)
31. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203-8. (PMID: 9743539)
32. Speiser DE, Liénard D, Pittet MJ, Batard P, Rimaldi D, Guillaume P, Lejeune F, Cerottini JC, Romero P. In vivo activation of melanoma specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32:731-41. (PMID: 11870617)
33. Bell EB, Sparshott SM, Bunce C. CD4+ T-cell memory, CD45R subsets and the persistence of antigen-a unifying concept. Immunol Today 1998; 19: 60-4. (PMID: 9509759)
34. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997; 186: 1407-18. (PMID: 9348298)
35. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Mobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G. Skewed maturation of memory HIV-specific CDS T lymphocytes. Nature 2001; 410: 106-11. (PMID: 11242051)
36. Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 2003; 3: 12. (PMID: 12962476)
37. McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 1994; 189: 75-91. (PMID: 7924438)
38. Flynn KJ, Belz GT, Altman KD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998; 8: 683-91. (PMID: 9658482)
39. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000; 60: 3559-68. (PMID: 10910069)
40. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-300. (PMID: 10570323)
41. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9: 540-7. (PMID: 12692546)
42. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999; 163: 6867-75. (PMID: 10586088)
43. Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 2000; 6 Suppl 1 : S76-80. (PMID: 10685664)
44. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002; 188: 122-35. (PMID: 12445286)
45. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002; 188: 177-82. (PMID: 12445291)
46. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64. (PMID: 12445281)
47. Kundig TM, Althage A, Hengartner H, Zinkernagel RM. Skin test to assess virus-specific cytotoxic T-cell activity. Proc Natl Acad Sci U S A 1992; 89: 7757-61. (PMID: 1323850)
48. Romero P, Dunbar PR, Valmori D, Pittet MJ, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J Exp Med 1998; 188: 1641-50. (PMID: 9802976)
49. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AM, Keilholz U. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 2000; 244: 81 -9. (PMID: 11033021)